



MOLECULAR CANCER DIAGNOSTIC
FOR SOLID TUMORS

[64
Genes]

OncoGxOne™ analyzes a patient's tumor for genetic mutations found in cancers.

- Profiles clinically relevant mutations in 56 genes to guide the selection of targeted therapies.
- Assays 8 genes with pharmacogenomics (PGx) information to help predict response to chemotherapies.
- Detects all mutation types, including SNV, Indel, gene fusion, and CNV.
- Average depth of coverage exceeds 250x resulting in mutation detection with high specificity and sensitivity.

Targeted Therapies Available for Cancer Subtypes:

Brain Cancer

- Glioma
- Medulloblastoma

Breast Cancer

Digestive System

- Colorectal Cancer
- Esophageal Cancer
- Gastrointestinal Stromal Tumor (GIST)

Gynecological

- Endometrial Cancer
- Ovarian Cancer
- Squamous Cell Cervical Cancer

Lung Cancer

- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer

Neuroblastoma

Renal Cell Carcinoma

Sarcoma

- Liposarcoma
- Rhabdomyosarcoma

Skin Cancer

- Basal Cell Carcinoma
- Melanoma

Prostate Cancer

Thyroid Cancer

OncoGxOne™ Gene List:

| | | | |
|--------|--------|--------|--------|
| ABL1 | CEBPA | GNAQ | NPM1 |
| AKT1 | CRLF2 | HRAS | NRAS |
| ALK | CTNNB1 | IDH1 | PDGFRA |
| ATM | DDR2 | IDH2 | PDGFRB |
| AURKA | DNMT3A | JAK1 | PIK3CA |
| BCL2 | EGFR | JAK2 | PTCH1 |
| BCL6 | ERBB2 | KIT | PTEN |
| BCR | ESR1 | KMT2A | RARA |
| BRAF | ETV6 | KRAS | RET |
| BRCA1 | FGFR1 | MAP2K1 | ROS1 |
| BRCA2 | FGFR2 | MET | RUNX1 |
| CCND1 | FGFR3 | MPL | SMO |
| CCNE1 | FLT3 | MYC | TP53 |
| CDK4 | GNA11 | NF1 | TSC1 |
| CYP2C8 | DYPD | TPMT | UGT1A1 |
| CYP2D6 | MTHFR | TYMS | XRCC1 |

PGx Genes

Proprietary Bioinformatics Analysis:



SNV



CNV



Fusion



Indel

Interpretation Powered by N-of-One:

- Industry leading clinical interpretation
- Most up-to-date scientific and clinical evidence
- Incorporates relevant guidelines
- Clinical trial match with location prioritization





FDA Approved Targeted Therapies

| | | |
|--------------------------------------|--------------------------------|-----------------------------------|
| Ado-trastuzumab emtansine (Kadcyla®) | Goserelin (Zoladex®) | Regorafenib (Stivarga®) |
| Afatinib (Gilotrif®) | Imatinib (Gleevec®) | Ruxolitinib (Jakafi®) |
| Alectinib (Alecensa®) | Ipilimumab (Yervoy®) | Sirolimus (Rapamune®) |
| Anastrozole (Arimidex®) | Lapatinib (Tykerb®) | Sorafenib (Nexavar®) |
| Bosutinib (Bosulif®) | Lenvatinib (Lenvima®) | Sunitinib (Sutent®) |
| Cabozantinib (Cometriq®) | Letrozole (Femara®) | Tamoxifen (Soltamox®; Nol-vadex®) |
| Ceritinib (Zykadia®) | Leuprolide (Lupron®; Eligard®) | Temsirolimus (Torisel®) |
| Cetuximab (Erbixux®) | Nilotinib (Tasigna®) | Tofacitinib (Xeljanz®) |
| Cobimetinib (Cotellic®) | Nintedanib (OFEV®) | Toremifene (Fareston®) |
| Crizotinib (Xalkori®) | Nivolumab (Opdivo®) | Trametinib (Mekinist®) |
| Dabrafenib (Tafinlar®) | Olaparib (Lynparza®) | Trastuzumab (Herceptin®) |
| Dasatinib (Sprycel®) | Osimertinib (Tagrisso®) | Tretinoin; ATRA (Vesanoid®) |
| Erlotinib (Tarceva®) | Palbociclib (Ibrance®) | Vandetanib (Caprelsa®) |
| Everolimus (Zortress®; Affinitor®) | Panitumumab (Vecti-bix®) | Vemurafenib (Zelboraf®) |
| Exemestane (Aromasin®) | Pazopanib (Votrient®) | Vismodegib (Erivedge®) |
| Fulvestrant (Faslodex®) | Pertuzumab (Perjeta®) | |
| Gefitinib (Iressa®) | Ponatinib (Iclusig®) | |

FDA Approved Chemotherapies

| | | |
|------------------------------|---------------------------|--------------------------------|
| Arsenic trioxide (Trisenox®) | Docetaxel (Taxotere®) | Paclitaxel (Onxol®; Abraxane®) |
| Capecitabine (Xeloda®) | Fluorouracil (5-FU®) | Mercaptopurine (Purinethol®) |
| Carboplatin (Paraplatin®) | Irinotecan (Camptosar®) | Thioguanine (Tabloid®) |
| Cisplatin (Platinol®) | Leucovorin (Wellcoverin®) | |
| Cyclophosphamide (Endoxan®) | Oxaliplatin (Eloxatin®) | |

Select Drugs in Clinical Trials

| | | |
|---------------------------|--------------------------|------------------------|
| Crenolanib (CP-868-596) | Ganetespi (STA-9090) | Retaspimycin (IPI-504) |
| Dacomitinib (PF-00299804) | Neratinib (HKI-272) | Rociletinib (CO-1686) |
| Dinaciclib (SCH-727965) | Quizartinib (AC220) | Selumetinib (AZD6244) |
| Dovitinib (TKI258) | Refametinib (BAY86-9766) | Tanespimycin (17-AAG) |

